[1]
|
Spiegelman, B.M. and Flier, J.S. (1996) Adipogenesis and obesity: Rounding out the big picture. Cell, 87, 377-389. doi:10.1016/S0092-8674(00)81359-8
|
[2]
|
Goldberg, I.J. (1996) Lipoprotein lipase and lipolysis: Central roles in lipoprotein metabolism and atherogenesis. Journal of Lipid Research, 37, 693-707.
|
[3]
|
Hara, T., Cameron-Smith, D., Cooney, G.J., Kusunoki, M., Tsutsumi, K., et al. (1998) The actions of a novel lipoprotein lipase activator, NO-1886, in hypertriglyceridemic fructosefed rats. Metabolism, 47, 149-153.
doi:10.1016/S0026-0495(98)90211-6
|
[4]
|
Peterson, J., Fuji-moto, W.Y. and Brunzell, J.D. (1992) Relationship of activity, heparin affinity, and conformation as studied with monoclonal antibodies. Journal of Lipid Research, 33, 1165-1170.
|
[5]
|
Sparkes, R.S., Zollman, S., Klisak, I., Kir-chgessner, T.G., Komaromy, M.C., et al. (1987) Human genes involved in lipolysis of plasma lipoproteins: Mapping of loci for lipoprotein lipase to 8p22 and hepatic lipase to 15q21. Genomics, 1, 138-144.
doi:10.1016/0888-7543(87)90005-X
|
[6]
|
Wion, K.L., Kir-chgessner, T.G., Lusis, A.J., Schotz, M.C. and Lawn, R.M. (1987) Human lipoprotein lipase complementary DNA sequence. Science, 235, 1638-1641.
doi:10.1126/science.3823907
|
[7]
|
Senda, M., Oka, K., Brown, W.V., Qasba, P.K. and Furuichi, Y. (1987) Molecular cloning and sequence of cDNA coding for bovine lipoprotein lipase. Proceedings of the National Academy of Sciences of the United States of America, 84, 4369-4373. doi:10.1073/pnas.84.13.4369
|
[8]
|
Clarke, A.R., Luscombe, M. and Holbrook, J.J. (1983) The effect of the chain length of he-parin on its interaction with lipoprotein lipase. Biochimica et Biophysica Acta, 747, 130-137. doi:10.1016/0167-4838(83)90131-0
|
[9]
|
Pedersen, M.E., Co-hen, M. and Schotz, M.C. (1983) Immunocytochemical localization of the functional fraction of lipoprotein lipase in the perfused heart. Journal of Lipid Research, 24, 512-521.
|
[10]
|
Brunzell, J.D. (1995) Familial lipoprotein lipase deficiency and other causes of chylomicromia syndrome. In: Scriver, C.R., Baudette, A.L., Sly, W.S. and Valle, D., Eds., The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill, New York, 1913-1932.
doi:10.1016/S0307-4412(96)80019-7
|
[11]
|
Nikkil?, E.A., Taskinen, M.R. and Kekki, M. (1978) Relation of plasma high-density lipoprotein cholesterol to lipoprotein-lipase activity in adipose tissue and skeletal muscle of man. Atherosclerosis, 29, 497-501.
|
[12]
|
Kusunoki, M., Tsutsumi, K., Sato, D., Nakamura, A., Habu, S., et al. (2011). Activation of lipoprotein lipase increases serum high density lipoprotein 2 cholesterol and enlarges high density lipoprotein 2 particles in rats. European Journal of Pharmacology, 668, 337-339.
doi:10.1016/j.ejphar.2011.06.040
|
[13]
|
Tsutsumi, K., Inoue, Y., Shima, A., Iwasaki, K., Kawamura, M., et al. (1993) The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. Journal of Clinical Investigation, 92, 411-417.
doi:10.1172/JCI116582
|
[14]
|
Raynolds, M.V., Awald, P.D., Gordon, D.F., Gutierrez- Hartmann, A., Rule, D.C., et al. (1990) Lipoprotein lipase gene expression in rat adipocytes is regulated by isoproterenol and insulin through different mechanisms. Molecular Endocrinology, 4, 1416-1422.
doi:10.1210/mend-4-9-1416
|
[15]
|
Tsutsumi, K., Inoue, Y., Shima, A. and Murase, T. (1995) Correction of hypertriglyceri-demia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetes rats. Diabetes, 44, 414-417.
doi:10.2337/diabetes.44.4.414
|
[16]
|
Miesenb?ck, G., H?lzl, B., F?ger, B., Brandst?tter, E., Paulweber, B., et al. (1993) Hete-rozygous lipoprotein lipase deficiency due to a missense muta-tion as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities. Journal of Clinical Investigation, 91, 448-455. doi:10.1172/JCI116222
|
[17]
|
Katzel, L.I., Busby-Whitehead, M.J., Rogus, E.M., Krauss, R.M. and Gold-berg, A.P. (1994) Reduced adipose tissue lipoprotein lipase responses, postprandial lipemia, and low high-density lipo-protein-2 subspecies levels in older athletes with silent myo-cardial ischemia. Metabo- lism, 43, 190-198. doi:10.1016/0026-0495(94)90244-5
|
[18]
|
Reymer, P.W., Gagné, E., Groenemeyer, B.E., Zhang, H., Forsyth, I., et al. (1995) A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nature Genetics, 10, 28-34. doi:10.1038/ng0595-28
|
[19]
|
Gaziano, J.M., Hennekens, C.H., O’Donnell, C.J., Bres- low, J.L. and Buring, J.E. (1997) Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation, 96, 2520-2525.
doi:10.1161/01.CIR.96.8.2520
|
[20]
|
Fan, J., Unoki, H., Kojima, N., Sun, H., Shimoyamada, H., et al. (2001) Overexpression of lipoprotein lipase in transgenic rabbits inhibits diet-induced hypercholestero- lemia and atherosclerosis. The Journal of Biological Chemistry, 276, 40071-40079.
doi:10.1074/jbc.M105456200
|
[21]
|
Shimada, M., Shimano, H., Gotoda, T., Yamamoto, K., Kawamura, M., et al. (1993) Over-expression of human lipoprotein lipase in transgenic mice. Resistance to dietinduced hypertriglyceridemia and hyper-cholesterolemia. The Journal of Biological Chemistry, 268, 17924-17929.
|
[22]
|
Shimada, M., Ishibashi, S., Inaba, T., Yagyu, H., Harada, K., et al. (1996) Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. Proceedings of the National Academy of Sciences of the United States of America, 93, 7242-7246. doi:10.1073/pnas.93.14.7242
|
[23]
|
Tsutsumi, K., Inoue, Y., Hagi, A. and Murase, T. (1997) The novel compound NO-1886 elevates plasma high- density lipoprotein cholesterol levels in hamsters and rabbits by increasing lipoprotein lipase without any effect on cholesteryl ester transfer protein activity. Metabolism, 46, 257-260. doi:10.1016/S0026-0495(97)90250-X
|
[24]
|
Shimokawa, H. and Vanhoutte, P.M. (1989) Impaired endothelium-dependent relaxation to aggregating platelets and related vasoactive substances in porcine coronary arrteries in hypercholesterolemia and atherosclerosis. Circulation Research, 64, 900-914.
doi:10.1161/01.RES.64.5.900
|
[25]
|
Lakatta, E.G. and Yin, F.C. (1982) Myocardial aging: Functional alterations and related cellular mechanisms. The American Journal of Physiology, 242, H927-H941.
|
[26]
|
Moritoki, H., Tanioka, A., Maeshiba, Y., Iwamoto, T., Ishida, Y., et al. (1988) Age-associated decrease in hista- mine-induced vasodilation may be due to reduction of cyclic GMP formation. British Journal of Pharmacology, 95, 1015-1022. doi:10.1111/j.1476-5381.1988.tb11734.x
|
[27]
|
Hara, T., Kusunoki, M., Tsutsumi, K., Okada, K., Sakamoto, S., et al. (1998) A lipoprotein lipase activator, NO-1886, improves en-dothelium-dependent relaxation of rat aorta associated with aging. European Journal of Pharmacology, 350, 75-79.
doi:10.1016/S0014-2999(98)00230-1
|
[28]
|
Kusunoki, M., Tsutsumi, K., Hara, T., Ogawa, H., Nakamura, T., et al. (2002) A lipoprotein lipase activator, NO-1886 prevents impaired en-dothelium-dependent relaxation of aorta caused by exercise in aged rats. Experimental Gerontology, 37, 891-896.
doi:10.1016/S0531-5565(02)00023-2
|
[29]
|
Ohta, T., Takata, K., Horiuchi, S., Morino, Y. and Matsuda, I. (1989) Protective effect of lipoproteins containing apoprotein A-I on Cu2+-catalyzed oxidation of human low density lipoprotein. FEBS Letters, 257, 435-438.
doi:10.1016/0014-5793(89)81590-X
|
[30]
|
Chiba, T., Miura, S., Sawamura, F., Uetsuka, R., Tomita, I., et al. (1997) Antiathero-genic effects of a novel lipo- protein lipase-enhancing agent in cholesterol-fed New Zealand white rabbits. Atherosclerosis, Thrombosis, and Vascular Biology, 17, 2601-2608.
doi:10.1161/01.ATV.17.11.2601
|
[31]
|
Yin, W., Tsutsumi, K., Yuan, Z. and Yang, B. (2002) Ef- fects of the lipoprotein lipase activator NO-1886 as a suppressor agent of atherosclerosis in aorta of mild dia- betic rabbits. Arzneimittelforschung, 52, 610-614.
doi:10.1055/s-0031-1299939
|
[32]
|
White, R.T., Damm, D., Hancock, N., Rosen, B.S., Lowell, B.B., et al. (1992) Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. The Journal of Biological Chemi-stry, 267, 9210-9213.
|
[33]
|
Friedman, J.M. (2000) Obesity in the new millennium. Nature, 404, 632-634. doi:10.1038/35017505
|
[34]
|
Shimomura, I., Funahashi, T., Takahashi, M., Maeda, K., Kotani, K., et al. (1996) Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nature Medicine, 2, 800-803.
doi:10.1038/nm0796-800
|
[35]
|
Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Ban- erjee, R.R., et al. (2001) The hor-mone resistin links obesity to diabetes. Nature, 409, 307-312.
doi:10.1038/35053000
|
[36]
|
Hotamisligil, G.S. (1999) The role of TNFα and TNF receptors in obesity and insulin resistance. Journal of Internal Medicine, 245, 621-625.
doi:10.1046/j.1365-2796.1999.00490.x
|
[37]
|
Scherer, P.E., Williams, S., Fogliano, M., Baldini, G. and Lodish, H.F. (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. The Journal of Bio- logical Chemistry, 270, 26746-26749.
doi:10.1074/jbc.270.45.26746
|
[38]
|
Kern, P.A., Ong, J.M., Saffari, B. and Carty, J. (1990) The effect of weight loss on the activity and expression of adipose-tissue lipoprotein lipase in very obese humans. The New England Journal of Medicine, 322, 1053-1059.
doi:10.1056/NEJM199004123221506
|
[39]
|
Sadur, C.N., Yost, T.J. and Eckel, R.H. (1984) Insulin responsiveness of adipose tissue lipoprotein lipase is de- layed but preserved in obesity. The Journal of Clinical Endocrinology and Metabolism, 59, 1176-1182.
doi:10.1210/jcem-59-6-1176
|
[40]
|
Shimada, M., Ishibashi, S., Yamamoto, K., Kawamura, M., Watanabe, Y., et al. (1995) Overexpression of human lipoprotein lipase increases hor-mone-sensitive lipase activity in adipose tissue of mice. Bio-chemical and Bio- physical Research Communications, 211, 761-766.
doi:10.1006/bbrc.1995.1878
|
[41]
|
Jensen, D.R., Schlaepfer, I.R., Morin, C.L., Pennington, D.S., Marcell, T., et al. (1997) Prevention of diet-induced obesity in transgenic mice overex-pressing skeletal muscle lipoprotein lipase. The American Journal of Physiology, 273, R683-R689.
|
[42]
|
Ferrano, R.T., Eckel, R.H., Larson, D.E., Fontvieille, A.M., Rising, R., et al. (1993) Relationship between ske- letal muscle lipoprotein lipase activity and 24-hour mac- ronutrient oxidation. The Journal of Clinical Investiga- tion, 92, 441-445. doi:10.1172/JCI116586
|
[43]
|
Kusunoki, M., Hara, T., Tsutsumi, K., Nakamura, T., Miyata, T., et al. (2000) The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resis- tance in rats fed a high-fat diet. Diabetologia, 43, 875- 880. doi:10.1007/s001250051464
|
[44]
|
Boss, O., Muzzin, P. and Giacobino, J.P. (1998) The un- coupling proteins, a re-view. European Journal of Endo- crinology, 139, 1-9. doi:10.1530/eje.0.1390001
|
[45]
|
Schrauwen, P. and Hesselink, M. (2002) UCP2 and UCP3 in muscle controlling body meta-bolism. The Journal of Experimental Biology, 205, 2275-2285.
|
[46]
|
Doi, M., Kondo, Y. and Tsutsumi, K. (2003) Lipoprotein lipase activator NO-1886 (ibrolipim) accelerates the mRNA expression of fatty acid oxidation-related enzymes in rat liver. Metabolism, 52, 1547-1550.
doi:10.1016/j.metabol.2003.07.007
|
[47]
|
Kusunoki, M., Tsut-sumi, K., Iwata, K., Yin, W., Nakamura, T., et al. (2005) NO-1886 (ibrolipim), a lipoprotein lipase activator, increases the expression of uncoupling protein 3 in skeletal muscle and suppresses fat accumula- tion in high-fat diet-induced obesity in rats. Metabolism, 54, 1587-1592. doi:10.1016/j.metabol.2005.06.005
|
[48]
|
Spiegelman, B.M. (1998) PPAR-γ: Adipogenic regulator and thiazolidinedione receptor. Diabetes, 47, 507-514.
doi:10.2337/diabetes.47.4.507
|
[49]
|
Miyazaki, Y. and Defronzo, R.A. (2008) Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipo-cytokines in type 2 diabetic patients. Diabetes, Obesity & Me-tabolism, 10, 1204-1211. doi:10.1111/j.1463-1326.2008.00880.x
|
[50]
|
Boden, G. and Zhang, M. (2006) Recent findings con- cerning thiazolidine-diones in the treatment of diabetes. Expert Opinion on Investi-gational Drugs, 15, 243-250.
doi:10.1517/13543784.15.3.243
|
[51]
|
Hermansen, K. and Mortensen, L.S. (2007) Bodyweight changes associated with antihyperglycemic agents in type 2 diabetes mellitus. Drug Safety, 30, 1127-1142.
doi:10.2165/00002018-200730120-00005
|
[52]
|
Hallakou, S., Doaré, L., Foufelle, F., Kerqoat, M., Guerre-Millo, M., et al. (1997) Pioglitazone induces in vitro adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes, 46, 1393-1399.
doi:10.2337/diabetes.46.9.1393
|
[53]
|
Kusunoki, M., Tsutsumi, K., Sato, D., Nakamura, A., Habu, S., et al. (2011) Pioglita-zone-induced body weight gain is prevented by combined ad-ministration with the lipoprotein lipase activator NO-1886. European Journal of Pharmacology, 668, 486-491.
doi:10.1016/j.ejphar.2011.07.030
|
[54]
|
Kusunoki, M., Tsutsumi, K., Nakayama, M., Kurokawa, T., Nakamura, T., et al. (2007) Relationship between se- rum concentrations of saturated fatty acids and unsatu- rated fatty acids and the homeostasis model insulin resis- tance index in Japanese patients with type 2 di-abetes mel- litus. The Journal of Medical Investigation, 54, 243-247.
doi:10.2152/jmi.54.243
|
[55]
|
Sato, D., Nakamura, T., Tsutsumi, K., Shinzawa, G., Karimata, T., et al. (2012) Site dependency of fatty acid composition in adipose triacylglycerol in rats and its absence as a result of high-fat feeding. Metabolism, 61, 92-98. doi:10.1016/j.metabol.2011.05.012
|
[56]
|
Matsuzaka, T., Shi-mano, H., Yahagi, N., Kato, T., Atsumi, A, et al. (2007) Crucial role of a long-chain fatty acid elongase, Elovl6, in obesi-ty-induced insulin resistance. Nature Medicine, 13, 1193-1202. doi:10.1038/nm1662
|